AcquisitionOther
Provention Bio, Inc. acquired Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Provention Bio, Inc. -> Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment · $25.00
The transaction adds an innovative, fully owned, first-in-class therapy in type 1 diabetes to Sanofi's core asset portfolio in General Medicines and further drives its strategic shift toward products with a differentiated profile.
Open source record (SEC) ↗